Medical treatment of dyslipidemia in the elderly
Journal of Geriatric Neurology · 2022
DOI: 10.53991/jgn.2022.00129 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Geriatric Neurology, 2022. Verfasst von Han Jun Kim und 1 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Worldwide, the proportion of the population aged 65 years or older is rapidly increasing, along with the prevalence of dyslipidemia and cardiovascular disease. Because of decreased physiological functions and comorbidities in the elderly, it is difficult to determine a treatment strategy for each individual. According to the guidelines for dyslipidemia in Europe and the United States, aggressive low-density lipoprotein cholesterol lowering is recommended for secondary prevention of cardiovascular disease as in the younger patient group. Also, newer cholesterol-lowering agents, ezetimibe and PCSK9 inhibitor can be added to achieve treatment goals in high risk groups. However, considering the conflicting study results in primary prevention, it is necessary to fully consider life expectancy and side effects of medications to determine whether to initiate treatment. Several on-going studies are expected to give answers to many complex clinical situations of dyslipidemia treatment in the elderly.
Zitieren
APA
Kim, H. J., & Kim, C. K. (2022). Medical treatment of dyslipidemia in the elderly. Journal of Geriatric Neurology. https://doi.org/10.53991/jgn.2022.00129
Vancouver
Kim HJ, Kim CK. Medical treatment of dyslipidemia in the elderly. Journal of Geriatric Neurology. 2022. doi:10.53991/jgn.2022.00129
BibTeX
@article{Kim2022,
author = {Kim, Han Jun and Kim, Chi Kyung},
title = {Medical treatment of dyslipidemia in the elderly},
journal = {Journal of Geriatric Neurology},
year = {2022},
doi = {10.53991/jgn.2022.00129}
}
EUVIMED